

VCBeat Health Contact Us

China Healthcare Select

Vertical Industries 

Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory

Home CSPC Pharmaceutical: Biased Amylin Agonist SYH2092 Receives NMPA IND Approval for Obesity Treatment

CSPC Pharmaceutical: Biased Amylin Agonist SYH2092 Receives NMPA IND Approval for Obesity Treatment

Jun 06, 2026 07:56 CST Updated 09:54

Share:

CSPC

Innovative Drug Research and Development, Manufacturer

vcbeatglobal@vcbeat.net 

SERVICES

Partnership Development Market Entry Advisory Ecosystem Engagement Advisory

COMPANY

About VCBeat Why VCBeat Contact Us

CHANNELS

China Healthcare Select Insights MNC China Lens Events VB100 GMPC

MORE

PRIVACY VCBEAT CHINA

© 2025 VCBeat. All rights reserved.